Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aslan Pharmaceuticals Ltd ADR
(NQ:
ASLN
)
0.6152
-0.0158 (-2.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
470,921
Open
0.6100
Bid (Size)
0.6010 (9)
Ask (Size)
0.6152 (3)
Prev. Close
0.6310
Today's Range
0.5900 - 0.6477
52wk Range
0.3920 - 4.690
Shares Outstanding
402,116,835
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
March 27, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
March 16, 2024
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug...
Via
Talk Markets
Performance
YTD
+11.85%
+11.85%
1 Month
+29.54%
+29.54%
3 Month
+23.34%
+23.34%
6 Month
-67.62%
-67.62%
1 Year
-76.70%
-76.70%
More News
Read More
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
March 12, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
March 11, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 06, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
March 06, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
February 29, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
February 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 12, 2024
Via
Benzinga
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
January 08, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
January 02, 2024
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 15, 2023
Via
Benzinga
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
December 12, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 04, 2023
Via
Benzinga
ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
November 03, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
October 27, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 24, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
October 18, 2023
From
ASLAN PHARMACEUTICALS LIMITED
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.